Recognition of technology and corporate growth value from two evaluation agencies designated by the exchange
[팜뉴스=이권구 기자] Weigencell (CEO Kim Tae-gyu), a company specializing in immune cell therapy, announced on the 22nd that it has passed the technology evaluation for a special listing of technology.
According to Weigencell, as a result of being evaluated in various fields such as technology maturity and growth potential, business growth potential, and manpower level from two specialized evaluation institutions designated by the Korea Exchange, it has obtained A and BBB grades from two evaluation institutions, respectively, to provide technological prowess and enterprise. Has been recognized for its growth value and passed the technology evaluation.
Weigencell is a company specializing in immune cell therapy, founded by Professor Tae-gyu Kim, who is considered a world-renowned authority in the field of immunology, and Boryeong Pharmaceutical participated as a financial investor in 2016. Last year, it was awarded the Bio Grand Prize awarded by the Minister of Food and Drug Safety at the 2020 Korea New Drug Medical Awards.
Weigencell is a customized T cell therapy platform technology’ViTier’ using antigen-specific cytotoxic T cells (CTL),’ViMedier’, a universal immunosuppressive cell therapy platform technology, and a universal T cell based on gamma delta T cells. Based on three platform technologies such as’ViRanger’, a cell therapy platform technology, six new drugs are currently being developed.
As a major new drug pipeline,’VT-EBV-N’, a treatment for’NK/T cell lymphoma’, a rare and intractable disease without standard treatment, is undergoing phase 2 clinical trials, and was designated as an orphan drug in the development stage by the Ministry of Food and Drug Safety in October 19th. It is expected to be commercialized quickly with conditional product approval after completion of phase 2 clinical trials. In addition, a 1/2a clinical trial was approved last year for’VMGD’, an immune cell therapy product that uses’GvHD’ as an indication, which is mainly seen in bone marrow transplant patients. 1)-A’ also received approval for a phase 1 clinical trial last year, and plans to start a clinical trial this year.
Tae-gyu Kim, CEO of Weigen Cell, said, “Based on the passing of this technology evaluation, we plan to promote listing within the third quarter. He said, “We plan to increase the corporate market value by concentrating our capabilities on discovering new drugs using technology.”
Weigencell plans to request a preliminary listing review on the Korea Exchange in April, and aims to be listed on the KOSDAQ within the third quarter of this year.
Copyright © Farm News Unauthorized reproduction and redistribution prohibited